Overview
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
Status:
Completed
Completed
Trial end date:
2014-11-01
2014-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Erlotinib Hydrochloride
Criteria
Inclusion Criteria:- It is the physician's decision to prescribe erlotinib in participants and to document
their treatment
- Participants must be candidates for receiving erlotinib for locally advanced or
metastatic non-small cell lung cancer according to the product label
Exclusion Criteria:
- Participants will be excluded if safety concerns occurred
- If the participant was not compliant or if the participant would wish to stop
erlotinib therapy